JYNT · JOINT Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. The Joint Corp. reported Q2 2026 revenue growth of 14% to $15.2M and a $1.4M increase in Adjusted EBITDA from continuing operations to $1.5M as refranchising nears completion, while system-wide sales declined 3.7% to $180.0M and comp sales were (2.8)%. The company reiterated full-year 2026 guidance for system-wide sales, comps, and Adjusted EBITDA, but lowered new franchised clinic openings to 22-26 from prior 30-35.
- + Revenue grew 14% year-over-year to $15.2M, reflecting the shift to the pure-play franchisor revenue model
- + Adjusted EBITDA from continuing operations rose by $1.4M to $1.5M, underscoring operating leverage in the new franchisor model
- + Cash flow from operating activities grew 152% to $2.2M, driving free cash flow of $1.9M (+$1.6M YoY)
- + Refranchising substantially complete, positioning the company as a capital-light, pure-play franchisor
- + Disciplined capital allocation with $677K in share repurchases and three RD territory buybacks in the quarter
- − System-wide sales declined 3.7% to $180.0M year-over-year
- − Comp sales remained negative at (2.8)% in Q2 2026
- − New franchised clinic openings guidance lowered to 22-26 from prior 30-35
- − Selling and marketing expenses surged 40% year-over-year to $4.9M
- − Net loss from continuing operations of $251K and clinic count net decline expected for 2026
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JYNT
this stock
JOINT Corp
|
$111.02M | -10.0% | +16.2% | 29.1 | 2.8% |
|
HCA
HCA Healthcare, Inc.
|
$94.71B | -8.6% | +7.1% | 14.7 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.49B | -8.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.23B | +32.7% | +0.9% | 10.2 | 2.3% |
|
EHC
Encompass Health Corp
|
$12.01B | +14.7% | +10.5% | 19.8 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JYNT | -5.2% | -6.8% | -4.4% | -7.0% | -10.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -4.0% | -5.0% | -22.2% | -6.6% | -22.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.